'As expected, there have been hiccups along the way. Last August, the New York-based biotech announced topline data from a phase 2 study of OV101, its Angelman program. The data came from 88 patients after 12 weeks of treatment and showed that OV101 beat placebo on one measure but failed to do so on 16 other metrics.'
This kind of says it all, going on to P3 with only 1 of 16 hits in primary outcomes at P2 is, let's say, bold, in my view.
It is worth reading up about Tonic inhibition and the role of UBE3A in Angelman's, a task I've just started, with thanks to Piton and Hottod.
OVID FAIL, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.65 |
Change
-0.540(2.81%) |
Mkt cap ! $2.383B | |||
| Open | High | Low | Value | Volume |
| $18.98 | $19.15 | $18.50 | $10.51M | 560.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $18.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.65 | 1127 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |